Citi downgrades Vertex Pharmaceuticals Inc (Nasdaq: VRTX) from Buy to Hold. Price target dropped from $52 to $25.

This article: 113 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE